News | August 23, 2021
Zydus gets USFDA approval for arthritis drug
Zydus was the first to file an ANDA for Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength
Zydus was the first to file an ANDA for Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
Lenalidomide is used to treat cancer and also some anaemia disorders
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
The group has a total of 320 ANDA approvals
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Anti-malaria API facility will be operational in 15-18 months
The collaboration will support Canada with direct access to rapid pandemic response capabilities
The group now has 320 approvals and has so far filed over 400 ANDAs
Subscribe To Our Newsletter & Stay Updated
